The Effect of Factor Xa Inhibition, With Rivaroxaban, on the Pathology of Sickle Cell Disease
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2016
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Beta-thalassaemia; Sickle cell anaemia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 02 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 02 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.